We have generated an optimized inducible recombination system for conditional gene targeting based on a Cre recombinase±steroid receptor fusion. This con®guration allows ef®cient Cre-mediated recombination in most organs of the mouse upon induction, without detectable background activity. An ES cell line, was established that carries the inducible recombinase and a loxP-¯anked lacZ reporter gene. Out of this line, completely ES cellderived mice were ef®ciently produced through tetraploid blastocyst complementation, without the requirement of mouse breeding. Our ®ndings provide a new concept allowing the generation of inducible mouse mutants within 6 months, as compared to 14 months using the current protocol.
INTRODUCTION
Conditional gene targeting has become increasingly used in reverse mouse genetics, as it facilitates setting the site and time of gene inactivation in the body (1±3). This is achieved by the expression of the site-speci®c DNA recombinase Cre in conjunction with the target gene containing two Cre recognition sites (loxP). In the conditional mouse mutant, inactivation of the target gene is restricted in a spatial and/or temporal manner, depending on the expression pattern of the recombinase. Since the initial demonstration of this technology in 1994 (4) , an increasing number of conditional knockout experiments have been published, most of which employed tissue-speci®c promoters to control Cre expression. Spatially regulated gene inactivation has proven to be powerful in dissecting the role of different cell types in a physiological process, as demonstrated for example by studies concerning the role of insulin receptor signaling in glucose homeostasis (5) . The method of choice for precise gene function analyses in adult mice, however, is the temporal control of gene inactivation as it can prevent impaired embryonic development until the time of induction. In particular, inducible gene targeting in all organs would be a useful tool if the major site of gene action is not precisely de®ned. Optimally, such a system should permit a tight control of gene inactivation, ef®cient recombination in every single cell of the body upon induction, and the opportunity to produce suf®cient numbers of inducible mouse mutants within a short time.
The major drawback of the current strategy is the long time frame required for the derivation of a conditional mouse mutant. Since two copies of the loxP-¯anked allele must be combined with the recombinase transgene, at least three breeding steps (3 months each) are required to obtain a reasonable number of mice with the desired genotype (see Fig. 5A ). While the ®rst conditional mouse mutants can be expected within 14 months, additional time for breeding is usually needed to obtain suf®cient numbers of mice for phenotypic analysis. To date, only a few mouse strains permitting ubiquitously inducible gene targeting are available, all of which suffer from incomplete recombination upon induction or background activity in the absence of inducer (6±10). Recently, a mouse strain has been generated by the insertion of a tamoxifen-inducible CreER fusion protein gene into the ubiquitously expressed Rosa26 gene (11) . While this strain represented the most ef®cient tool for ubiquitously inducible gene targeting so far, a low af®nity ER domain was used that requires high doses of the inducer 4-hydroxytamoxifen to achieve the maximal rate of recombination. Therefore, the side effects of the inducer may interfere with the phenotypic outcome of target gene inactivation. Taken together, there is a need for improved methods which both enable ef®cient gene knockout in all organs at non-toxic concentrations of the inducer and which accelerate the production of inducible mouse mutants.
In this paper we describe a novel approach for the rapid generation of inducible mouse mutants, which overcomes the drawbacks of the current technology. The approach is based on a ubiquitously expressed, high af®nity CreER fusion protein that allows the ef®cient inducible inactivation of a loxP-¯anked target gene in most organs. In addition, we demonstrate that hybrid ES cells tolerate at least three consecutive gene targeting cycles including selection with the antibiotics G418 and hygromycin B without affecting the potency to complement tetraploid blastocysts. Our ®ndings provide a new concept allowing the rapid production of ES cell-derived, inducible knockout mice.
MATERIALS AND METHODS

Construction of vectors
CreER T2 . The Cre gene was ampli®ed by PCR (Expand High Fidelity PCR system; Clontech) from PGKCrebpA using the oligos PR-A (TAACTAGCGGCCGCGTCGACCATGTCC-AATTTACTGACCGTACAC) and creER5 (TCTCATGTCT-CCAGCAGAATCGCCATCTTCCAGCAGGCG). In parallel the ER domain was ampli®ed from the CreED2 vector (12) using the oligos creER4 (CTGGAAGATGGCGATTCTGC-TGGAGACATGAGAGCTGCC) and creER1 (TAGTTAG-CGGCCGCTCAGACTGTGGCAGGGAAACCCTC). Both PCR products were used as overlapping templates in a PCR with the primers PR-A and creER1. The resulting 2 kb product was digested with NotI and inserted into the NotI site of pBS. Site-directed mutagenesis (Stratagene) was applied to introduce a G400V mutation using primers ER-G400Vs (CATGGAGCACCCAGTGAAGCTACTGTTTG) and ERG400Vas (CAAACAGTAGCTTCACTGGGTGCTCCATG). For the introduction of two amino acid changes, M543A/ L544A, the primers ER AA2¢ s EagI (ATGACCTGCTG-CTGGAGGCGGCCGACGCCCACCGCCTAC) and ER AA2 as EagI (GTAGGCGGTGGGCGTCGGCCGCCTCCAGCA-GCAGGTCAT) were used in a site-directed mutagenesis. The creER T2 was inserted into an expression vector containing a CMV promoter, an intron and a polyadenylation signal resulting in the vector CMV-CreER.
Rosa targeting vector.
A 129 SV/EV-BAC library (Incyte Genomics) was screened with a probe against exon 2 of the Rosa26 locus [ampli®ed from mouse genomic DNA using Rscreen1s (GACAGGACAGTGCTTGTTTAAGG) and Rscreen1as (TGACTACACAATATTGCTCGCAC)]. Out of the identi®ed BAC clone an 11 kb EcoRV subfragment was inserted into the HindII site of pBS. Two fragments (a 1 kb SacII±XbaI and a 4 kb XbaI fragment) were used as homology arms and inserted into a vector consisting of a FRT-¯anked neomycin resistance gene (unpublished) and a splice acceptor site from adenovirus (13) .
CreER T2 knock-in vector. The CreER T2 coding sequence and a polyadenylation site was inserted into the Rosa-targeting vector.
Rosa(lacZ reporter) knock-in vector. The neo gene of the Rosa-targeting vector was deleted through transformation of FLP-expressing bacteria (14) . In the resulting vector a cassette containing a loxP-¯anked PGK-hygro-pA followed by lacZ was inserted.
ect2 Targeting vector. The vector was generated by insertion of PCR fragments (with attached restriction sites) ampli®ed from BAC DNA (129SVJ) into a vector consisting of a FRTanked neomycin resistance gene¯anked by two loxP sites (G. Kauselmann, unpublished results). The 989 bp PCR fragment of the 5¢ targeting arm was inserted with NotI/SgfI 5¢ of the loxP sites and the 4023 bp PCR fragment of the 3¢ arm with XhoI/PmeI 3¢ of the loxP sites. The 428 bp PCR fragment of exon 6 and the¯anking intronic region were inserted with AscI/FseI between the loxP sites.
Cell culture
Culture and targeted mutagenesis of ES cells were carried out as previously described (15) with ES cell lines derived from both inbred and F 1 embryos.
Generation of ect2¯o x ES cells. The C57BL/6 cell line Bruce4 was electroporated with the described targeting vector, and out of 480 clones 3 homologous recombined clones were detected.
Mice
All mice were kept in the animal facility at Artemis Pharmaceuticals GmbH in microisolator cages (Tecniplast Sealsave). B6D2F1 mice for the generation of tetraploid blastocysts were obtained from Janvier. The polb¯o x / rosa(CreER T2 ) and ect2¯o x /rosa(CreER T2 ) mice were generated by breeding of rosa(CreER T2 ) ES mice with bT14 (4) and ect2¯o x females (unpublished), respectively.
Production of ES mice by tetraploid embryo complementation
The production of mice by tetraploid embryo complementation was essentially performed as described (16) .
Ligand administration
An aliquot of 100 mg tamoxifen-free base (T5648; Sigma) was suspended in 100 ml ethanol and dissolved in 1 ml sun¯ower oil (Sigma). This 10 mg/100 ml tamoxifen solution was sonicated for 1±2 min and then stored at ±20°C. For p.o. administration the solution was thawed at 55°C and administrated to 4±8-week-old mice by a feeding needle (18061-20FST; Fine Science Tools GmbH).
Western blot analysis
Western blot analysis was performed using SDS±PAGE (NuPAGE; Invitrogen) and the Breeze Immunodetection System (Invitrogen) according to the manufacturer's protocols. Immunodetection was done using HC-20 against ER, PRB-106C against cre, I-19 against actin and rabbit polyclonal IgG antibodies (Santa Cruz Biotechnology Inc.).
RESULTS
Design of F 1 ES cells carrying an inducible Cre transgene
To derive an optimized system for inducible gene targeting in mice, we generated a fusion protein consisting of Cre recombinase and the mutated ligand-binding domain of the estrogen receptor ER T2 (17) . The ER T2 domain is composed of amino acids 282±595 of the human estrogen receptor and carries three mutations (G400V/M543A/L544A) that confer a 10Q enhanced sensitivity to the synthetic ligand 4-hydroxytamoxifen in mice as compared to the previously used ER T (G521R) domain (18) . The CreER T2 coding region was inserted into the ubiquitously expressed Rosa26 locus through homologous recombination to obtain a con®guration that allows the inducible inactivation of genes in all organs (Fig. 1) . The Rosa26 targeting vector containing the CreER T2 gene is depicted in Figure 1A . We used the hybrid ES cell lines V6. these lines are capable of producing completely ES cellderived mice (ES mice) through tetraploid blastocyst complementation with high ef®ciency (16) . Independent recombinant ES cell clones were obtained at a frequency of 2% as veri®ed by Southern blot analysis (Fig. 1B) . Deletion of the neo gene did not affect the level of CreER T2 expression as determined by western blot analysis (Fig. 1D) . A loxP-¯anked hygromycin resistance gene was introduced into the second allele of Rosa26 (Fig. 1A and C) to provide a similar test substrate for Cre as the widely used Rosa26 reporter (19, 20) . In ES cells carrying both the rosa(CreER T2 ) and the rosa(lacZ reporter) alleles, complete recombination of the loxP-¯anked segment was achieved upon treatment with 500 nM 4-hydroxytamoxifen for 4.5 days (Fig. 1E) . Half-maximal activation of CreER T2 occurred at a concentration of 10 nM 4-hydroxytamoxifen (Fig. 1F ) as compared to 100 nM for the CreER T fusion protein (12) .
Generation of ES cell-derived mice
The three types of recombinant and wild-type V6.5 and ART4.12 ES cells were injected into tetraploid blastocysts and ES mice were obtained upon transfer of these blastocysts into pseudopregnant females. The proportion of transferred blastocysts that further developed into live born pups was in 
the range 8±17% and did not signi®cantly decrease when ES cells were used that had undergone up to three sequential rounds of transfection ( Fig. 2A) . In contrast, the production of ES mice using inbred ES cells was inef®cient (0.2%), con®rming the`hybrid vigor' effect described in Eggan et al. (16) (Fig. 2A) . Southern blot analysis of genomic DNA using a Rosa26-speci®c probe showed that the V6.5/CreER/¯ox ES mice were indeed solely derived from the recombinant ES cells and did not contain any detectable tetraploid cells from the injected blastocysts (Fig. 2B ). These results demonstrate that mice can be produced by tetraploid blastocyst complementation using cells that have undergone three consecutive rounds of transfection, including two drug selection cycles.
Ubiquitously inducible gene targeting in mice
For the induction of CreER T2 in mice, we applied 1±5 mg tamoxifen orally for 5 days in the following experiments. We preferred to use this protocol, as the LD 50 of tamoxifen in mice is 15-fold higher via the oral route than by i.p. injection (200 mg versus 5 g/kg) (21) . It has been recently demonstrated that the oral application of tamoxifen is as ef®cient as i.p. injection of 4-hydroxytamoxifen for the activation of CreER (22) . Rosa(CreER T2 /lacZ reporter) mice were fed with daily 5 mg tamoxifen for 5 days and recombination of the lacZ reporter was analyzed 3 days after the last administration. Southern analysis of genomic DNA from different organs showed up to 50% recombination, without detectable background activity in untreated animals (Fig. 3A) . This is a signi®cantly higher degree of inducible recombination as compared to the results obtained with the Rosa26-CreER T strain (11), indicating that the ER T2 domain is indeed more sensitive to 4-hydroxytamoxifen. Upon recombination, the lacZ gene turned out to be inserted non-functionally, presumably due to a second start codon upstream of the coding region.
Since the Rosa26 locus has a limited accessibility for Cre (11), we were interested to test the rosa(CreER T2 ) con®gur-ation in the context of other loxP-¯anked loci. As the second substrate, we used the loxP-¯anked DNA polymerase b gene segment (polb¯o x ) (4). This allele had been used to characterize a number of tissue-speci®c (4,12,23±26) as well as inducible Cre strains (6, 12) , and shows an intermediate accessibility for Cre (F. Schwenk and J. Seibler, unpublished observations). The polb¯o x /rosa(CreER T2 ) mice were fed with 5 mg tamoxifen/day for 5 days and analyzed 3 days later. Southern blot analysis revealed that the loxP-¯anked polymerase b gene segment was excised in more than 90% of cells in all organs except brain, whereas no background recombination was detected in untreated mice (Fig. 3B) . As a third substrate, we used a 2.5 kb loxP-¯anked segment of the ect2 gene. Again, up to 100% recombination in most tissues was achieved upon tamoxifen treatment of ect2¯o x /rosa(CreER T2 ) mice, without detectable background recombination in uninduced controls (Fig. 3C) . A similar degree of recombination was achieved when a shorter (0.5 kb) loxP-¯anked segment in the same position of the ect2 gene was used (Fig. 3D) .`Low dose application' of 5 Q 1 mg tamoxifen was suf®cient to achieve complete recombination of the ect2¯o x allele in most organs, further demonstrating the improved sensitivity of the ER T2 domain in vivo.
To investigate whether the low recombination ef®ciency in brain was due to low CreER T2 expression we performed western analysis using antibodies speci®c for the human estrogen receptor. The 74 kDa band corresponding to the CreER T2 fusion protein was detectable in all organs including brain, with the highest levels in thymus, small intestine and testis (Fig. 4) . The limited degree of recombination in brain may thus re¯ect a lower local concentration of 4-hydroxytamoxifen rather than a reduced expression level of CreER T2 .
DISCUSSION
We describe an optimized system that allows ubiquitously inducible gene targeting in mice. This system is based on a fusion protein consisting of Cre recombinase and a mutated ligand-binding domain of the estrogen receptor that is Figure 3 . Inducible recombination in mice. Mice carrying different loxP-¯anked alleles were fed daily with 5 mg tamoxifen (A±D) or 1 mg tamoxifen (E) for 5 days. Cre-mediated deletion of the loxP-¯anked region was detected by Southern analysis 3 days after the treatment. (A) Rosa(CreER T2 /lacZ reporter) mice. Genomic DNA from various organs was digested with EcoRV and hybridized with a lacZ-speci®c probe. The percentages of deletion of the loxP-¯anked allele, as quanti®ed with a Bio-Imaging Analyzer, are indicated. (B) polb¯o x /rosa(CreER T2 ) mice. Cre-mediated excision of the 1.5 kb loxP-¯anked region was detected by Southern analysis. Genomic DNA from various organs was digested with BamHI and hybridized with a probe speci®c for the polymerase b gene (4). (C) ect2¯o x /rosa(CreER T2 ) mice. The loxP sites are 2.5 kb apart from each other¯anking a FRT-¯anked neomycin selection marker and exon 6 of the ect2 gene (described in Materials and Methods). Genomic DNA was digested with HpaI and hybridized with an ect2-speci®c probe hybridizing upstream of the loxP-¯anked region. (D) ect2¯o x D neo /rosa(CreER T2 ) mice. The ect2¯o x D neo allele was generated through FLP-mediated deletion of the neomycin selection marker from the ect2¯o x allele resulting in a loxP-¯anked region of 0.5 kb containing exon 6 of the ect2 gene (described in Materials and Methods). Genomic DNA was digested with HpaI and hybridized with an ect2-speci®c probe. (E) ect2¯o x /rosa(CreER T2 ) mice treated with 1 mg tamoxifen for 5 days. Genomic DNA was digested with HpaI and hybridized with an ect2-speci®c probe hybridizing upstream of the loxP-¯anked region. Li, liver; Sp, spleen; Ki, kidney; He, heart; Lu, lung; Th, thymus; Mu, muscle; Si, small intestine; Br, brain; Te, testis; Co, colon.
expressed under the control of the ubiquitously active Rosa26 promoter (19) . In contrast to the Rosa26-CreER T mouse strain published by Vooijs et al. (11), we used the ER T2 domain that responds at an~10-fold lower dose of the synthetic inducer 4-hydroxytamoxifen as compared to the ER T domain (17, 18) . In mice, the rosa(CreER T2 ) con®guration achieved nearly complete inducible excision of multiple loxP-¯anked gene segments in all organs except brain, without background recombination in the absence of inducer (Fig. 3) . Thus, our system permits the tight temporal control of ubiquitous gene The current protocol includes the generation of targeted ES cells, the FLP-mediated deletion of the neo gene, the production of chimeric mice, the breeding for germline transmission and another two breeding steps to combine two copies of the loxP-¯anked allele with the recombinase transgene. Following this scheme, the generation of conditional mouse mutants usually takes 14 months. Chimeras can be directly bred to Cre transgenic mice supposing that appropriate Cre strains on pure genetic backgrounds are available that allow the detection of germline transmission by coat color. This would save 3 months required for one breeding step. inactivation, allowing precise gene function analysis in animals that have undergone normal embryonic development. The lower degree of deletion observed with the Rosa26 allele (lacZ reporter) con®rms the position dependency of Cremediated recombination described by Vooijs et al. (11) . Since all other targets tested so far achieved near complete excision with the rosa(CreER T2 ) con®guration (Fig. 2 and unpublished  observations) , a limited accessibility may be restricted to only a minority of loxP-¯anked loci. As the rosa(CreER T2 ) allele permits inducible gene inactivation in all organs, it should ®nd broad application as a research tool in reverse mouse genetics.
We have employed the tetraploid blastocyst complementation approach for in vivo analysis of the rosa(CreER T2 ) con®guration, allowing the generation of ES cell-derived mice (ES mice) in a single step without the requirement of timeconsuming breeding. Tetraploid blastocysts are not capable of completing normal development, but, when complemented by the introduction of diploid ES cells, support the development of solely ES cell-derived mice. The ef®cient generation of such ES mice using non-transgenic hybrid ES cells has been recently demonstrated (16) . In this study, the authors also succeeded in generating a single ES mouse through tetraploid blastocyst complementation using transfected cells that had undergone two consecutive rounds of selection. However, it remained unclear whether ES cells maintain their potency to complement tetraploid embryos with suf®cient ef®ciency and reproducibility even after additional genetic modi®cations, which is a prerequisite for the strategy depicted in Figure 5B . We introduced both the CreER T2 coding region and a lacZ reporter construct into hybrid ES cells by targeted insertion into the Rosa26 locus. The targeting strategy involved three consecutive rounds of transfection and selection with the antibiotics G418 and hygromycin B. We found that all targeted ES cell clones produced ES-derived mice with high ef®ciency. The proportion of transferred blastocysts that developed into live born pups was in the range 8±17% and did not signi®cantly decrease using ES cells that had undergone three consecutive transfections ( Fig. 2A) . Thus, we demonstrate that hybrid ES cells can be exposed to at least three transfection cycles without affecting the potency to complement tetraploid embryos, allowing the analysis of complex genetic alterations in ES cell-derived mice within the time of a single mouse generation.
Our ®ndings provide the proof of principle for a new concept allowing the rapid production of inducible knockout mice using tetraploid blastocyst complementation. So far, the derivation of conditional mouse mutants had been a timeconsuming undertaking since three breeding steps (3 months each) are usually required to obtain mice combining two copies of the loxP-¯anked allele and the recombinase transgene (Fig. 5A) . To address this limitation, we propose a new strategy that involves the tetraploid blastocyst complementation approach for the one step generation of conditional mouse mutants from genetically engineered ES cells. The generation of ES cells from Cre transgenic mice is feasible using standard protocols (15) , as demonstrated by O'Gorman and colleagues (27) . Three transfection cycles are suf®cient to introduce loxP sites into both alleles of the target gene in ES cells, following the strategy depicted in Figure 5B . Thus, by using Cre transgenic ES cell lines for the generation of the loxP-¯anked alleles, it will be possible to produce conditional mouse mutants directly from the targeted ES cells through tetraploid blastocyst complementation. Using this scheme, adult (2 months old) inducible mouse mutants available for phenotypic analyses can be obtained within 6 months, required for three gene targeting steps (1 month each) and one mouse generation time (3 months) (Fig. 5B) . This saves more than 50% of time as compared to the current conditional gene targeting protocol, which requires 14 months including two targeting steps and four mouse generations (Fig. 5A) . Since the described approach is simple and technically not more demanding than the current knockout protocol, we expect that this strategy will become a widely used tool in reverse mouse genetics.
